Revolution Medicines announces $2.225 billion concurrent offerings of common stock and convertible notes

"Davis Polk LLP advised the representatives of J.P. Morgan Securities, TD Cowen and Guggenheim Securities in Revolution Medicines’ SEC-registered offerings of 12,147,887 common shares ($1.725B) and $500M 0.50% convertible senior notes due 2033. Proceeds will be used for general corporate purposes."

Davis Polk LLP advised the representatives of the several underwriters — J.P. Morgan Securities LLC, TD Cowen and Guggenheim Securities, LLC — in connection with concurrent SEC-registered offerings by Revolution Medicines, Inc. The transaction comprised an offering of 12,147,887 shares of common stock by Revolution Medicines for an aggregate gross proceeds of $1.725 billion and a separate SEC-registered offering of $500 million aggregate principal amount of 0.50% convertible senior notes due 2033. The offerings were conducted concurrently and the proceeds will be used for general corporate purposes. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. Davis Polk LLP represented the representatives of the several underwriters (J.P. Morgan Securities LLC, TD Cowen and Guggenheim Securities, LLC) with a team composed by: partners Alan F. Denenberg and Yasin Keshvargar and associates Paula Gergen, Brendon S. Brown, Hannah R. Carter and Naomi Zhao (capital markets); partner Lucy W. Farr, counsel Yixuan Long and associate Valentin Van de Walle (tax advice); and partner David R. Bauer (intellectual property advice). Members of the Davis Polk team were based in the Northern California and New York offices.

Menu

Revolution Medicines announces $2.225 billion concurrent offerings of common stock and convertible notes

Read the full story

Menu

Revolution Medicines announces $2.225 billion concurrent offerings of common stock and convertible notes

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads